As part of our Antenatal Screening offerings and in alignment with the new guidelines, Australian Clinical Labs is now offering Placental Growth Factor (PIGF 1-2-3™ assay-DELFIA Xpress®) blood test from PerkinElmer. Along with the combined First Trimester Screening (cFTS) and Harmony Non-Invasive Prenatal Testing (NIPT), PIGF is an additional first trimester screening marker. PIGF can be used to screen for Early-Onset Pre-Eclampsia (EO-PE) in pregnancy.

Pre-Eclampsia (PE)

Pre-Eclampsia (PE) is a multi-system disorder previously identified by the onset of hypertension accompanied by significant proteinuria after 20 weeks of gestation. In 2014, the definition of PE was broadened by the International Society for the Study of Hypertension in Pregnancy (ISSHP) (Table 1) and adopted by the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) as it is considered a major cause of death and morbidity for the mother and perinatal death and long-term handicap for the baby. In the absence of proteinuria, the finding of maternal organ dysfunction is sufficient to make the diagnosis of PE.

International Society for the Study of Hypertension in Pregnancy (ISSHP) revised definition of PE, 2014

The revised ISSHP definition of pre-eclampsia (2014) is:

Hypertension developing after 20 weeks gestation and the coexistence of one or more of the following new onset conditions:

1. Proteinuria
2. Other maternal organ dysfunction:
   - renal insufficiency (creatinine >90 umol/L)
   - liver involvement (elevated transaminases and/or severe right upper quadrant or epigastric pain)
   - neurological complications (examples include eclampsia, altered mental status, blindness, stroke, or more commonly hyperreflexia when accompanied by clonus, severe headaches when accompanied by hyperreflexia, persistent visual scotomata)
   - haematological complications (thrombocytopenia, DIC, haemolysis)
3. Uteroplacental dysfunction
   - foetal growth restrictions

Table 1: Quoted from Tranquilli AL et al. 2014

Pre-Eclampsia is a Spectrum Disorder

PE Can Be Sub-Classified Into:

- Early-Onset PE (with delivery at <34+0 weeks of gestation)
- Pre-Term PE (with delivery at <37+0 weeks of gestation)
- Late-Onset PE (with delivery at ≥34+0 weeks of gestation)
- Term PE (with delivery at ≥37+0 weeks of gestation)

These sub-classifications are not mutually exclusive. Early Onset PE (EO-PE) is associated with a much higher risk of short and long term maternal and perinatal morbidity and mortality. 2,3,4

Pre-Eclampsia is More Common than Aneuploidies

The prevalence of PE and related conditions (fetal growth-restriction and pre-term birth) is much higher than that of Down syndrome. PE affects 2-8% of pregnancies globally. The incidence is increasing with the global increase in maternal age, obesity and the use of assisted reproductive techniques. It also follows the rising incidence of diabetes, hypertension, and renal disease – all are known co-morbidities that predispose sufferers to PE during pregnancy.

Unlike Down syndrome, PE is a major cause of maternal and perinatal morbidity and mortality. Thus, preventing PE would bring substantial improvements to maternal and perinatal health.

Pre-Eclampsia and Early Assessment

Screening for PE can be performed at 11-13+6 weeks’ gestation by a combination of maternal demographic characteristics and medical history with some biophysical markers including mean arterial blood pressure (MAP) and the mean uterine artery pulsatility index (UTPI) along with measurements of biochemical markers. NHMRC recommend an assessment to all women for clinical risk factors for PE early in pregnancy.

In June 2019, the International Federation of Gynecology and Obstetrics (FIGO) released new guidelines to combat PE.

- FIGO adopts and supports the Fetal Medicine Foundation (FMF) position that all pregnant women should be screened for pre-term PE by the first-trimester combined test with maternal risk factors, MPAP, UTPI, and PIGF as a one-step procedure.
- FIGO adopts and supports the FMF position that in high-risk women, defined by the first-trimester combined test, aspirin ~150 mg/night should be commenced at 11–14+6 weeks of gestation until either 36 weeks of gestation, when delivery occurs, or when PE is diagnosed.
- FIGO encourages all countries and its member associations to adapt and promote strategies to improve access to prenatal services and encourage early booking.
FIGO encourages all countries and its member associations to ensure that risk assessment and resource-appropriate testing for pre-PE become an integral part of routine first-trimester evaluation protocol offered at all maternal health services.

Biochemical Markers in Pre-eclampsia

Biochemical markers that reflect placental function, such as Placental Growth Factor (PIGF) and pregnancy associated plasma protein-A (PAPP-A), are significantly reduced in the first trimester, and throughout the pregnancy, in patients that will later present with pre-PE with delivery <37 weeks’ gestation.

Of these two markers PIGF is a better PE screening marker than PAPP-A (i.e. it has higher sensitivity)

Placental Growth Factor (PIGF) for Early Onset Pre-eclampsia (EO-PE) Screening

PIGF is a glycoprotein that belongs to the vascular endothelial growth factor (VEGF) subfamily. It is a potent angiogenic factor. It is expressed in the villous syncytiotrophoblast and in the media of larger stem vessels in the human placenta. PIGF, together with VEGF, regulates the development of the placental vasculature, and the result depends on intra-placental oxygen pressure.

PIGF concentrations increase throughout pregnancy, peaking during the third trimester, and falling thereafter, probably as a consequence of placential maturation. In PE or intrauterine growth restriction (IUGR), changes in expression or function of PIGF, as well as some other angiogenic factors, may interrupt the function of the utero-placental unit, and thus contribute to many adverse obstetric outcomes.

Why PIGF?

Several studies have shown that women who subsequently develop PE have significantly lower maternal PIGF concentrations in the first trimester than those with normal pregnancies.

A systematic review and meta-analysis demonstrated that PIGF is superior to the other biomarkers for predicting PE. Serum PIGF biomarker can identify up 75% of women who develop pre-term PE with delivery at <37 weeks, at a screen-positive rate of 10%.

The COMPARE Study

The COMPARE study states that the high negative predictive values (NPV) support the role of PIGF-based tests as ‘rule-out’ tests for PE. Among the tests compared, the DELFIA Xpress® PIGF 1-2-3™ assay has the highest NPV.

ASPRE Study

Using PIGF 1-2-3™ assay (PerkinElmer) in PE screening, ASPRE was the biggest prospective, randomised, placebo controlled trial that showed that use of aspirin was associated with a significant 62% reduction in the incidence of pre-term PE (<37 weeks GA) and an 82% reduction in the incidence of EO-PE (<34 weeks GA).

Recently, studies showed that the administration of aspirin in pregnancies at high risk of PE reduces the length of stay in the neonatal intensive care unit (NICU) by about 70% mainly through the prevention of EO-PE.

When to offer?

The optimal time for screening is 11-13+6 weeks of gestation.

Who to offer?

Patients with high blood pressure, advanced age pregnancy, high BMI, positive history of pre-eclampsia or eclampsia, diabetes or kidney disease, multiple pregnancies or IVF assisted pregnancies.

The PIGF test can be offered to pregnant women of any age or risk category. It can be ordered for all naturally conceived or in vitro fertilisation (IVF) singleton or twin pregnancies, including those with egg donors. PIGF test is currently viewed as a screening test and clinical interpretation is always recommended.

Can it be offered with cFTS?

Yes, the same blood sample can be used for the measurement of biochemical markers for both pre-eclampsia screening and aneuploidy Down syndrome screening.

Specimen Requirements:

Plain tube or serum gel 7 ml - The Placental Growth Factor (PIGF) costs $50 - Blood samples can be collected at any of our Australian Clinical Labs pathology collection centres

References

26. NIMH National Health and Medical Research Council, October 2017. Evidence Based Recommendations.

About the author

Assoc. Prof. Mirette Saad
MBBS (Hons), MD, MAACB, FRCPA, PhD.

Lab: Clayton

Areas Of Interest: Molecular Genetics, Cancer Genetics, Antenatal Screening, NIPT, Endocrine, Fertility Testing and Research, Medical Teaching

Speciality: Chemical Pathology

Phone: (03) 9538 6777

Email: Mirette.Saad@clinicallabs.com.au